Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Irritable Bowel Syndrome

  Free Subscription


1 Aliment Pharmacol Ther
1 Biomed Pharmacother
1 Br J Health Psychol
1 Clin Gastroenterol Hepatol
1 Crit Rev Anal Chem
1 Dig Liver Dis
1 Future Sci OA
1 Int J Pharm Pract
1 J Investig Med
1 Mil Med
1 Minerva Urol Nefrol
3 Neurogastroenterol Motil
1 Probiotics Antimicrob Proteins
1 Rev Med Interne
2 Scand J Gastroenterol
1 World J Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Aliment Pharmacol Ther

  1. CLEVERS E, Vaes B, Henrard S, Goderis G, et al
    Health problems associated with irritable bowel syndrome: analysis of a primary care registry.
    Aliment Pharmacol Ther. 2018 Mar 24. doi: 10.1111/apt.14612.
    PubMed     Text format     Abstract available

    Biomed Pharmacother

  2. KWON S, Hsieh YS, Shin YK, Kang P, et al
    Linalyl acetate prevents olmesartan-induced intestinal hypermotility mediated by interference of the sympathetic inhibitory pathway in hypertensive rat.
    Biomed Pharmacother. 2018;102:362-368.
    PubMed     Text format     Abstract available

    Br J Health Psychol

  3. HENRICH JF, Martin M
    Altered attentional control linked to catastrophizing in patients with irritable bowel syndrome.
    Br J Health Psychol. 2018 Mar 23. doi: 10.1111/bjhp.12307.
    PubMed     Text format     Abstract available

    Clin Gastroenterol Hepatol

  4. ALMARIO CV, Noah BD, Jusufagic A, Lew D, et al
    Cost-Effectiveness of Biomarker Tests for Irritable Bowel Syndrome with Diarrhea - A Framework for Payers.
    Clin Gastroenterol Hepatol. 2018 Mar 26. pii: S1542-3565(18)30281.
    PubMed     Text format     Abstract available

    Crit Rev Anal Chem

  5. KOGAWA AC, Salgado HRN
    Status of Rifaximin: A Review of Characteristics, Uses and Analytical Methods.
    Crit Rev Anal Chem. 2018 Mar 26:1-8. doi: 10.1080/10408347.2018.1447355.
    PubMed     Text format     Abstract available

    Dig Liver Dis

  6. HILZ MJ, Arbustini E, Dagna L, Gasbarrini A, et al
    Non-specific gastrointestinal features: Could it be Fabry disease?
    Dig Liver Dis. 2018 Mar 1. pii: S1590-8658(18)30209.
    PubMed     Text format     Abstract available

    Future Sci OA

  7. HOLTON KF, Cotter EW
    Could dietary glutamate be contributing to the symptoms of obsessive-compulsive disorder?
    Future Sci OA. 2018;4:FSO277.
    PubMed     Text format     Abstract available

    Int J Pharm Pract

  8. HANNA A, Hanna LA
    What, where and when? Using Google Trends and Google to investigate patient needs and inform pharmacy practice.
    Int J Pharm Pract. 2018 Mar 30. doi: 10.1111/ijpp.12445.
    PubMed     Text format     Abstract available

    J Investig Med

  9. TAN TK, Saps M, Lin CL, Wei CC, et al
    Risks of irritable bowel syndrome in children with infantile urinary tract infection: a 13-year nationwide cohort study.
    J Investig Med. 2018 Mar 26. pii: jim-2017-000703. doi: 10.1136/jim-2017-000703.
    PubMed     Text format     Abstract available

    Mil Med

  10. BERGER J, Carroll MP Jr, Champoux E, Coop CA, et al
    Extremely Delayed Diagnosis of Type II Hereditary Angioedema: Case Report and Review of the Literature.
    Mil Med. 2018 Mar 26. pii: 4954103. doi: 10.1093.
    PubMed     Text format     Abstract available

    Minerva Urol Nefrol

  11. LI Z, Huang W, Wang X, Zhang Y, et al
    The relationship between lower urinary tract symptoms and irritable bowel syndrome: a meta-analysis of cross-sectional studies.
    Minerva Urol Nefrol. 2018 Mar 28. pii: S0393-2249.18.03044.
    PubMed     Text format     Abstract available

    Neurogastroenterol Motil

  12. POLSTER A, Friberg P, Gunterberg V, Ohman L, et al
    Heart rate variability characteristics of patients with irritable bowel syndrome and associations with symptoms.
    Neurogastroenterol Motil. 2018 Mar 25:e13320. doi: 10.1111/nmo.13320.
    PubMed     Text format     Abstract available

  13. BRENNER DM, Dove LS, Andrae DA, Covington PS, et al
    Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
    Neurogastroenterol Motil. 2018 Mar 25:e13331. doi: 10.1111/nmo.13331.
    PubMed     Text format     Abstract available

  14. BELLINI M, Gambaccini D, Salvadori S, Bocchini R, et al
    Different perception of chronic constipation between patients and gastroenterologists.
    Neurogastroenterol Motil. 2018 Mar 25:e13336. doi: 10.1111/nmo.13336.
    PubMed     Text format     Abstract available

    Probiotics Antimicrob Proteins

  15. LEVENTOGIANNIS K, Gkolfakis P, Spithakis G, Tsatali A, et al
    Correction to: Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
    Probiotics Antimicrob Proteins. 2018 Mar 28. pii: 10.1007/s12602-018-9412.
    PubMed     Text format     Abstract available

    Rev Med Interne

  16. COSSERAT J, Du Breuil F, Validire P, Lenoir S, et al
    [Recurrent abdominal pain in an 88-year-old woman].
    Rev Med Interne. 2018 Mar 22. pii: S0248-8663(17)30568.
    PubMed     Text format    

    Scand J Gastroenterol

  17. THOMPSON DG, O'Brien S, Kennedy A, Rogers A, et al
    Radiation-induced enteropathy - how a low-FODMAP diet might help.
    Scand J Gastroenterol. 2018;53:377-378.
    PubMed     Text format     Abstract available

  18. BLACK CJ, Ford AC
    Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?
    Scand J Gastroenterol. 2018;53:140.
    PubMed     Text format    

    World J Gastroenterol

  19. PIRKOLA L, Laatikainen R, Loponen J, Hongisto SM, et al
    Low-FODMAP vs regular rye bread in irritable bowel syndrome: Randomized SmartPill((R)) study.
    World J Gastroenterol. 2018;24:1259-1268.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.